More Drug Safety Transparency: New Open-Access, Peer-Reviewed Journal to Post Clinical Trial Information

I hardly recognize science publishers many mergers have taken place so quickly.  But just got word of a new, free and open-access journal that should be a must-read for anyone in the industry.  Its goal is to disseminate results of clinical trials, but also results of drug-drug- interaction studies as well as pharmacokinetic studies.  For more information, here is the news release that "Wiley-Blackwell" issued today. Wiley-Blackwell to Launch Archives of Drug Information Journal to Increase Public Access to Latest Research from Pharmaceutical Industry   Hoboken, New Jersey“March 5, 2007 ” Wiley-Blackwell announced the launch of Archives of Drug Information (ADI), a new open access, freely available peer-reviewed journal, dedicated to publishing the results of drug studies. This journal will help to address requests for transparency voiced by societies, health care practioners, patients, media, and the government to disclose clinical trial information.   ADI is unique because it will publish not only results of clinical trials and drug studies, but also articles on inconclusive and/or negative clinical trials, early drug development, routine drug-drug interaction, pharmacokinetic studies, and other low-profile areas that are traditionally overlooked. The first articles will be published online April 2007.   ADI will provide an unbiased, scientific home for high-quality information that should be in the public domain but currently resides on file somewhere, says Dr. C. Michael Stein, Editor of Archives of Drug Information. It will also help prevent scientists in drug development from repeating mistakes or following the same blind alleys others have explored because that information has never been published. ADI will publish a broad range of research, including cellular, animal, and human studies.   While some government and pharmaceutical companies provide repositories to register clinical data and public databases to post clinical trial results, sources for independent publication are very limited.  As a result, the findings of many drug development studies and clinical trials remain unpublished. Archives of Drug Information will bridge this gap by publishing data from clinical trials thereby disclosing results promptly to the researcher, clinician and the public. With ADI, it will be possible for everyone to freely search every published article to locate specific trials, methods, and experimental results.   This new journal is an exciting opportunity for Wiley-Blackwell to help the medical and pharmaceutical communities advance the innovative work of drug discovery and to help patients and their families understand the risks and benefits of prescription medicines, says Sue Corbett, Vice President and Managing Director, Medicine, Wiley-Blackwell. Archives of Drug Information will become a resource for scientists, physicians, patients, and students worldwide by providing free access to information that has previously been inaccessible.   For more information on submitting papers, contact